سعر ليبيتور 40مجم 14 قرص 2025

Atorvastatin 40 mg oral tablets, an HMG-CoA reductase inhibitor (statin) used with diet to lower LDL cholesterol and reduce cardiovascular risk.

• To reduce the risk of MI, stroke, revascularization procedures and angina in adults with multiple risk factors for coronary heart disease but without clinically evident CHD.Population: AdultsDailyMed (U.S. National Library of Medicine)
• To reduce the risk of MI and stroke in adults with type 2 diabetes and multiple CHD risk factors but without clinically evident CHD.Population: Adults with type 2 diabetesDailyMed (U.S. National Library of Medicine)
• To reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization, hospitalization for congestive heart failure and angina in adults with clinically evident CHD.Population: Adults with clinically evident CHDDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (>= 2% and more than placebo): nasopharyngitis, arthralgia, diarrhoea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia and pharyngolaryngeal pain.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to atorvastatin or any excipient (anaphylaxis, angioneurotic oedema, erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported).International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk increases with age 65 or older, uncontrolled hypothyroidism, renal impairment, certain interacting drugs and higher doses; discontinue if CK is markedly elevated or myopathy is diagnosed or suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotizing myopathy has been reported rarely; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: transaminase increases and rare fatal and non-fatal hepatic failure; consider liver enzyme testing before starting and when clinically indicated.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CyclosporineMarkedly increases atorvastatin exposure and myopathy risk; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)
• GemfibrozilIncreased risk of myopathy/rhabdomyolysis; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)
• Tipranavir plus ritonavir; glecaprevir plus pibrentasvirMarkedly increase atorvastatin exposure; concomitant use is not recommended.DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognised (or consider the patient's ongoing therapeutic need); may cause fetal harm based on its mechanism, although observational statin data have not identified a risk of major congenital malformations.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Atorvastatin: Selective, competitive inhibitor of HMG-CoA reductase; lowers hepatic cholesterol synthesis and increases hepatic LDL receptors, enhancing LDL uptake (US LIPITOR label).